Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is studying icotinib following chemotherapy to see how well it
works compared to chemotherapy in treating patients with resected stage IIA-IIIA NSCLC
harboring EGFR mutation.